Dopamine receptor D1; Dopamine receptor D2 (DRD1, DRD2)

Dopamine receptor D1 and dopamine receptor D2 are prototypical members of the dopamine receptor family, broadly categorized as **D1-like** (DRD1) and **D2-like** (DRD2) subfamilies, each playing central roles in modulating central nervous system activity[1][3][4]. DRD1 preferentially couples to Gs proteins to stimulate adenylyl cyclase, enhancing cellular signaling, while DRD2 couples to Gi proteins, resulting in inhibition of adenylyl cyclase[1][2][6]. Both receptors are integral components of dopamine-mediated pathways governing mood, motivation, cognition, and motor function[3][4]. They are essential therapeutic targets in multiple disorders, including Parkinson’s disease, schizophrenia, and other neuropsychiatric and movement disorders[2][4][5]. Numerous drugs interact selectively or non-selectively with these receptors as agonists or antagonists (including antiparkinsonian and antipsychotic agents)[1][2][5]. While drug targeting of these receptors is clinically invaluable, it is complicated by safety and tolerability challenges such as movement disorders, cognitive side effects, and limitations in drug bioavailability[4][5].

Other names

D1 dopamine receptorD2 dopamine receptorD1RD2R

Agonism or partial agonism (stimulate D1 or D2 receptor activity); Antagonism or inverse agonism (inhibit D1 or D2 receptor activity); Modulation of G protein signaling (Gs for D1, Gi for D2)